InsidersTradesSigma
Total declarations
Company
▲ Purchases (5 ops.)
▼ Sales (6 ops.)
Insider track record
CEODisclosed buys
5
Disclosed sells
6
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the full record of transactions filed by Javitt Daniel C., Executive. Insider active across 1 company, notably NRX Pharmaceuticals, Inc.. Cumulatively, 18 disclosures have been recorded. Split: 5 buys · 6 sells. Total volume traded: €7.2m. Activity tracked since 1 June 2022. The latest transaction was disclosed on 17 December 2024 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Declarations18 total
40,000 shares@ US$1.170.7% of flowCommon StockSEC:0001415889-24-029694:0
Ideal exit: 13 Sept 2025 (T+270)
100,000 shares@ US$0.330.5% of flowCommon StockSEC:0001104659-23-094815:0
Ideal exit: 19 May 2024 (T+270)
200,000 shares@ US$0.3221.0% of flowCommon StockSEC:0001104659-23-094406:0
Ideal exit: 18 May 2024 (T+270)
400,000 shares@ US$1.006.4% of flowCommon Stock, par value $0.001 per shareSEC:0001415889-22-012324:0
13,730 shares@ US$1.50411.8% of flowcommon stockSEC:0000880984-22-000017:0
133,719 shares@ US$1.0211.6% of flowcommon stockSEC:0000880984-22-000015:0
49,200 shares@ US$1.00634.3% of flowcommon stockSEC:0000880984-22-000014:0
784,063 shares@ US$1.009468.4% of flowCommon StockSEC:0000880984-22-000009:0
2,000,000 shares0Common StockSEC:0000880984-22-000008:0
243,596 shares@ US$0.7024100.0% of flowCommon StockSEC:0000880984-22-000007:0
100,000 shares@ US$0.581.0% of flowCommon StockSEC:0000921895-22-001874:0
Ideal exit: 26 Feb 2023 (T+270)
100,000 shares@ US$58.0099.0% of flowCommon StockSEC:0000921895-22-001872:0
Ideal exit: 26 Feb 2023 (T+270)
434,594 sharesCommon StockSEC:0000950142-21-003505:0
434,594 sharesCommon StockSEC:0000950142-21-003505
13,971,864 sharesCommon StockSEC:0000950142-21-001944:0
13,971,864 sharesCommon StockSEC:0000950142-21-001944
46,332 sharesCommon StockSEC:0000950142-21-001945:0
46,332 sharesCommon StockSEC:0000950142-21-001945
18 of 18 declarations
About Javitt Daniel C.
Daniel C. Javitt is an executive at NRX Pharmaceuticals, Inc. Although he does not have a specified function, he contributes to the direction and strategy of the company. His role is essential in guiding strategic decisions and ensuring NRX Pharmaceuticals' performance.
